1. Ponikowski P, Voors AA., Anker S.D., Bueno H., Cleland J.G.F., Coats AJ.S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200. doi: 10.1093/eur-heartj/ehw128.
2. McMurray JJ. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail. 2015;17(3):242-247. doi: 10.1002/ejhf.250.
3. Reed B.N., Street S.E., Jensen B.C. Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure. Heart Fail Clin. 2014;10(4):543-557. doi: 10.1016/j.hfc.2014.07.002.
4. Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015;65(10):1029-1041. doi: 10.1016/j.jacc.2015.01.033.
5. Nikiforov V.S., Svistov A.S. Modern trends in the use of angiotensin-converting enzyme inhibitors in clinical practice. FARMindeks-Praktik = FARMindeks-Practician. 2005;(7):21-31. (In Russ.) Available at: https://www.pharmindex.ru/practic/7_cardio.html.